These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35253180)

  • 1. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
    Laganà AS; Monti N; Fedeli V; Gullo G; Bizzarri M
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1241-1247. PubMed ID: 35253180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F; Capozzi A; Canu A; Lello S
    Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H; Xing C; Zhang J; He B
    Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
    Fruzzetti F; Fidecicchi T; Palla G; Gambacciani M
    Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
    Genazzani AD; Battipaglia C; Petrillo T; Piacquadio N; Ambrosetti F; Arnesano M; Semprini E; Sponzilli A; Tomatis V; Simoncini T
    Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner's Results.
    Fedeli V; Catizone A; Querqui A; Unfer V; Bizzarri M
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
    Gateva A; Unfer V; Kamenov Z
    Gynecol Endocrinol; 2018 Jul; 34(7):545-550. PubMed ID: 29309199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S; Immediata V; Romualdi D; Policola C; Tropea A; Di Florio C; Tagliaferri V; Scarinci E; Della Casa S; Lanzone A; Apa R
    Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inositols: From Established Knowledge to Novel Approaches.
    Dinicola S; Unfer V; Facchinetti F; Soulage CO; Greene ND; Bizzarri M; Laganà AS; Chan SY; Bevilacqua A; Pkhaladze L; Benvenga S; Stringaro A; Barbaro D; Appetecchia M; Aragona C; Bezerra Espinola MS; Cantelmi T; Cavalli P; Chiu TT; Copp AJ; D'Anna R; Dewailly D; Di Lorenzo C; Diamanti-Kandarakis E; Hernández Marín I; Hod M; Kamenov Z; Kandaraki E; Monastra G; Montanino Oliva M; Nestler JE; Nordio M; Ozay AC; Papalou O; Porcaro G; Prapas N; Roseff S; Vazquez-Levin M; Vucenik I; Wdowiak A
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
    Cirillo F; Catellani C; Lazzeroni P; Sartori C; Tridenti G; Vezzani C; Fulghesu AM; Madeddu E; Amarri S; Street ME
    Gynecol Endocrinol; 2020 Jul; 36(7):588-593. PubMed ID: 32054355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML; Soulage CO
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
    Artini PG; Obino MER; Micelli E; Malacarne E; Vacca C; Papini F; Cela V
    Gynecol Endocrinol; 2020 Sep; 36(9):755-759. PubMed ID: 32157927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
    Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
    Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V; Porcaro G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
    Lei W; Gao Y; Hu S; Liu D; Chen Q
    Medicine (Baltimore); 2020 Jul; 99(30):e20696. PubMed ID: 32791663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M; Nordio M; Pajalich R
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.